# **Developing Flow Cytometry Assays for ATMPs: A Best Practice Guide for the Cell and Gene Therapy Community**



# Vorthern Advanced Therapies Treatment Centre

# **Identify assay purpose**

- Starting material characterisation
- In process control
- QC batch release
- Identity / purity / impurity / other
- Broader for information only characterisation
- Clinical samples

# **Panel development / Staining protocol**

- Purpose
  - Qualitative / quantitative / semiquantitative
- Single staining versus multiplexing
- Raw material selection
  - Pre-mixes / lyophilised antibodies
  - Single / dual suppliers
- Reference standards

# **System selection**

- Laser configuration
- Availability of equipment across CROs etc
- Continuity of supply of reagents etc.
- Qualification (IQ/PQ/OQ)
- Platform end of life migration
- **Comparability between systems such as** sensitivity

## **Data acquisition and analysis**

- Pre-run calibrations
- Flow rates / voltages
- Compensation
- Threshold and debris exclusion criteria
- Gating strategy /automated gating
- Novel data processing strategies

### Patient Protection

### 

# Sample knowledge


- Starting / process material variability
  - patient to patient
  - healthy vs diseased
  - media / buffers / excipients
  - prevalence of target cell population
- Method of sample acquisition
- Sample preparation effects
- **Distribution / transport effects**

### **Assay validation**

- Strategy
  - Before or parallel to process validation
- Protocol development
- **Requirements for dossier** 
  - How to present data
- Considerations for multi-site validation
  - Expected CVs between sites

- MESF
- **Exemplar patient materials**

- Data trending
- **Operator training / experience / learnings**
- **Ongoing standards development**
- **Ongoing technology developments**



This project has been funded by the Industrial Strategy Challenge Fund, part of the government's modern Industrial Strategy. The fund is delivered by UK Research and Innovation.

Cell and Gene Therapy Catapult is committed to ensuring high standards of research integrity and research best practice in the activities we carry out. We subscribe to the principles described in the UK concordat to support research integrity.

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154 4214 33.